申请人:ChemoCentryx, Inc.
公开号:US08198309B2
公开(公告)日:2012-06-12
Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
提供了作为CCR9受体的强效拮抗剂的化合物。动物测试表明,这些化合物对于治疗CCR9的标志性疾病炎症非常有用。这些化合物通常是芳基磺酰胺衍生物,可用于制备药物组合物、治疗CCR9介导的疾病的方法以及作为CCR9拮抗剂鉴定测定的对照物。